A 65-year-old man with chronic atrial fibrillation and a history of myocardial infarction (ejection fraction 35%) presents with recurrent episodes of ventricular tachycardia (VT) despite being on metoprolol 100 mg daily. His serum potassium is 3.8 mEq/L, magnesium is 2.0 mg/dL, and QTc interval is 420 ms. He is hemodynamically stable during the VT episode. What is the most appropriate next step in management?

Explanation

## Clinical Scenario Analysis This patient has **recurrent ventricular tachycardia (VT)** in the setting of: - **Prior myocardial infarction** (structural heart disease) - **Reduced ejection fraction (35%)** — heart failure - **Failure of beta-blocker monotherapy** (metoprolol 100 mg) - **Hemodynamic stability** during VT - **Normal electrolytes** (K⁺ 3.8, Mg²⁺ 2.0) and **normal QTc** (420 ms) ## VT Management Algorithm in Structural Heart Disease ```mermaid flowchart TD A[Ventricular Tachycardia]:::outcome --> B{Hemodynamically Stable?}:::decision B -->|No| C[Immediate DC Cardioversion]:::urgent B -->|Yes| D{Structural Heart Disease?}:::decision D -->|Yes| E[IV Amiodarone First-Line]:::action D -->|No| F[IV Procainamide or Sotalol]:::action E --> G[150 mg bolus over 10 min, then infusion]:::action F --> H[Consider alternatives if amiodarone contraindicated]:::action ``` ## Why Amiodarone is the Correct Choice **Key Point:** Amiodarone is the **first-line antiarrhythmic for hemodynamically stable VT in patients with structural heart disease** (prior MI, reduced EF) because: 1. **Broad-spectrum activity** — Class I, II, III, and IV properties 2. **Minimal negative inotropic effect** — safe in heart failure (unlike Class I agents) 3. **Proven efficacy** — superior to other agents in post-MI VT 4. **Hemodynamic stability** — maintains blood pressure better than other agents 5. **Evidence-based** — CAST trial showed Class I agents (flecainide, encainide) increase mortality in post-MI patients; amiodarone does not **High-Yield:** In patients with **structural heart disease and reduced EF**, amiodarone is preferred over Class I agents (procainamide) and Class III agents (sotalol) because it has the best safety profile and efficacy. ## Comparison of Antiarrhythmics in VT with Structural Heart Disease | Agent | Class | EF Effect | Safety in HF | Mortality Data | Use in This Case | |-------|-------|-----------|--------------|-----------------|------------------| | **Amiodarone** | I+II+III+IV | Minimal ↓ | Safe | No ↑ mortality | **First-line** | | **Procainamide** | Ia | Marked ↓ | Unsafe | CAST: ↑ mortality | Avoid in HF | | **Sotalol** | III + β-blocker | Moderate ↓ | Caution | Risk of torsades | Avoid (already on β-blocker) | | **DC Cardioversion** | — | — | Safe | — | Reserved for hemodynamic instability | **Clinical Pearl:** The **CAST trial (1989)** demonstrated that Class I antiarrhythmics (flecainide, encainide) increase mortality in post-MI patients despite suppressing arrhythmias. This landmark study established amiodarone as the preferred agent for VT in structural heart disease. ## Amiodarone Dosing for Acute VT **Mnemonic: "150-300-150" protocol** - **Acute VT (stable):** 150 mg IV bolus over **10 minutes** - If VT persists: 150 mg IV bolus over **10 minutes** (repeat once) - **Maintenance infusion:** 1 mg/min for 6 hours, then 0.5 mg/min **Warning:** Do NOT use sotalol in this patient because: 1. He is already on a beta-blocker (metoprolol) — additive beta-blockade risk 2. Sotalol causes QT prolongation — risk of torsades de pointes (though electrolytes are normal here) 3. Sotalol has negative inotropic effects — contraindicated in HF ## Why Other Options Are Suboptimal **Procainamide (Class Ia):** - Marked negative inotropic effect — dangerous in EF 35% - CAST trial showed increased mortality in post-MI patients - Reserved for hemodynamically stable VT in patients **without structural heart disease** **Sotalol (Class III + β-blocker):** - Redundant with existing metoprolol therapy - Risk of QT prolongation and torsades de pointes - Negative inotropic effect — contraindicated in HF - Not first-line in post-MI VT **DC Cardioversion:** - Appropriate only for **hemodynamic instability** (hypotension, altered consciousness, chest pain, pulmonary edema) - This patient is hemodynamically stable, so pharmacologic therapy is preferred initially - Can be used if amiodarone fails or if patient deteriorates